The Cystic Fibrosis Foundation said Wednesday that it would receive $3.3 billion for the sale of royalty rights to drugs developed with its financial support.. The payment is for the patient group’s share of revenue from cystic-fibrosis drugs like Kalydeco, which Vertex Pharmaceuticals Inc. developed with foundation funding. The foundation has committed $150 million to fund Vertex’s development of cystic fibrosis drugs, and has already paid the company more than $100 million, a Vertex spokesman said. Foundation Chief Executive...
  